CONSTELLATION TECHNOLOGIES LIMITED — Capital/Financing Update 2013

Oct 30, 2013

ASX Announcement

==> picture [99 x 86] intentionally omitted <==

31 October 2013

Agenix sells AGX -1009

Agenix Limited has entered into a binding term sheet with a Chinese pharmaceutical company to divest its AGX-1009 project, a tenofovir prodrug for hepatitis B, which has successfully completed pre-clinical trials. Definitive agreements are to be completed within 10 days.

Chairman and Chief Executive Nick Weston stated “This enables us to crystallise the value of this project with US $2 million payable in three tranches timed with the transfer of intellectual property. The sale of AGX-1009 is expected to be completed prior to 31 December 2013. All future project commitments transfer with the sale.”

About Agenix

Agenix listed on the Australian Securities Exchange in 1987. Today, Agenix’s lead product candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging modality for pulmonary embolism (PE) and deep vein thrombosis (DVT). ThromboView® has successfully completed two U. S. FDA Phase II clinical trials and is in partnering discussions for Phase III trials.

Agenix’s human health diagnostics platform, DiagnostIQ® is a patented disposable point-ofcare test device with reader. DiagnostIQ® utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a flow-through format to create a sensitive and quantitative, rapid, test. The patented technology provides the potential for point-of-need testing that is simple and quick to use, gives rapid and accurate results. Agenix has partnered with Arrayjet Limited (Scotland) to develop the device as a microarray platform. Agricultural rights for the platform are licensed to Bayer CropSciences AG.

For more information please contact:

Nicholas Weston Agenix Limited +61 3 8616 0379